YM Bioscience's EGFR-targeting Drug Goes Into Phase III Trials In Singapore
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - National Cancer Centre of Singapore will sponsor YM Bioscience's nimotuzumab for evaluation in a multinational Phase III trial of more than 700 patients with cancers of the head and neck, the company recently announced